Home
Contact Us
Aggregated China Business Blogs
2021-01-03
Will Kangmei Pharmaceutical's investor claim be the first class action case in China? There are disputes in these places
Aggregated Source:
Caishen.Co
Caishen.Co delivers
Primary Data for China`s Secondary Investment and Stock Markets
. Full details at
Caishen.Co
.
Original URL:
Click here to visit original article
Copyright
Caishen.Co
Related Posts
FT Features
Yuyue Medical’s transformation pains: frequent product quality issues, mergers and acquisitions to stimulate growth, there are drawbacks
Hillhouse Joins $100M Series C Round In Mobike As Bike Sharing Battle Heats Up
China’s HSBC Flash PMI Slips To 49.2 In March
Shaogang Songshan (000717.SZ): Li Guoquan resigns as vice president_NetEase
The stock price fell another 9% in early trading! Last year’s Q4 growth rate was lower than market expectations. Xiaoxiong Electric: Demand has slowed down
China offers show of naval force in South China Sea
Trump, Xi and a dark year for democracy
China weakens renminbi sharply
Three questions for Apple’s third-quarter earnings
SEARCH
Browse News
January 2021
S
M
T
W
T
F
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Dec
Feb »
Useful Sites
China Media Blog
China Legal Blog
China Travel Blog
Caishen.Co
ChinaPulse.com
ZhongjintouX.com